						(Rs. In Lacs)
Sr.				JDITED		AUDITED
No.	Particulars	Quarter	Quarter	Nine Months	Nine Months	Accounting
		ended on 31/12/2006	ended on 31/12/2005	ended on 12/31/2006	ended on 12/31/2005	Year ended on 31/03/2006
1	Gross Sales/Income from Operation	4,169.13	3,154.95	10,586.95	8,237.26	12,167.
	Less : Excise duty	216.88	181.87	606.57	445.72	653
	Net Sales/Income From Operations	3,952.25	2,973.08	9,980.38	7,791.54	11,513
	Other Income	41.00	80.04	121.73	107.83	110.
3	Total Expenditure	3,726.02	2,441.16	9,012.73	6,151.32	9,125
	a) (Increase)/Decrease in Stock in Trade b) Consumption of Raw Materials	(445.05) 3,739.65	(804.08) 2,793.65	(895.07) 8,634.57	(1,635.26) 6,728.08	(2,060 9,652
	c) Sales Tax & Other Taxes	112.97	64.24	246.56	168.55	241
	d) Staff cost	93.75	79.84	270.93	206.37	314
	e) Other expenditure	224.70	307.50	755.74	683.58	977
4	Interest	122.26	59.27	368.93	202.60	340
5	Depreciation	42.08	33.24	123.62	92.65	126
6	Profit before Tax	102.89	519.45	596.83	1,452.80	2,032
7	Provision for taxation - Current	28.94	-	167.89	-	657
	- Fringe benefit	0.50	-	1.51		3
	- Earlier Year - Deferred	-	0.52	-	0.52	0
8	- Deferred Net Profit after tax	73.45	518.93	427.43	1,452.28	32 1,338
_	Paid-up equity Share capital	73.45	772.40	772.40	772.40	772
9	(Face value Rs. 10/-)	112.40	112.40	112.40	112.40	112
10	Reserves excluding revaluation					3,934
_	reserves (As per Balance Sheet of previous					2,00
	accounting year)					
11	Earning per Equity Shares (EPS)					
	Basic	0.95	6.73	5.53	21.45	19
12	Diluted	0.95	6.73	5.53	21.45	18
	Aggregate of Non-Promoter Shareholding					
	- Number of Shares	4,667,700.00	4,679,600.00	4,667,700.00	4,679,600.00	4,680,900
	Percentage of Shareholding	60.43				
	SEGMENTWISE REVENUE, RESULTS AN			60.43 JDITED	6.59	(Rs. In Lacs)
		D CAPITAL EMPLOY	/ED	JDITED		(Rs. In Lacs) AUDITED Accounting year ende
	SEGMENTWISE REVENUE, RESULTS AN	D CAPITAL EMPLOY	/ED			(Rs. In Lacs)
	SEGMENTWISE REVENUE, RESULTS AN	D CAPITAL EMPLOY	/ED	JDITED		(Rs. In Lacs) AUDITED Accounting year ende
	SEGMENTWISE REVENUE, RESULTS AN	D CAPITAL EMPLOY	/ED	JDITED	ed 31/12/2006	(Rs. In Lacs) AUDITED Accounting year ende
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue	D CAPITAL EMPLOY Quarter ender	VED UNAL On 31/12/2006	JDITED Six months ende	ed 31/12/2006	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues	Quarter ender	UNAL d on 31/12/2006	Six months ende	ed 31/12/2006 59 .37	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results	Quarter ender	UNAL d on 31/12/2006	JDITED Six months ender	ed 31/12/2006 59 .37	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest	Quarter ended	UNAL UNAL UNAL UNAL UNAL UNAL UNAL UNAL	Six months ende 525 4721 9980	ed 31/12/2006 59 .37	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs	Quarter ended	UNAL d on 31/12/2006 11.07 11.18 52.25	Six months ende 525 4721 9980	ed 31/12/2006 59 .37 .38	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others	Quarter ended	UNAL I on 31/12/2006 11.07 11.18 52.25 4.87	Six months ender 525 4721 9980 761. 95.	ed 31/12/2006 59 .37 .38	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results	Quarter ended 177 222 399 155 44	UNAL UNAL UNAL UNAL UNAL UNAL UNAL UNAL	Six months ende 528 4721 9980 761. 95.	ed 31/12/2006 59 .37 .38 64 18	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others	Quarter ended 177 224 391 15 41 19	UNAL I on 31/12/2006 11.07 11.18 52.25 4.87	Six months ender 525 4721 9980 761. 95.	ed 31/12/2006 59 .37 .38 .64 18 .82	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and interest Bulk Drugs Others Total Segment Results Less: Interest	Quarter ended 177 22: 399 15 4 19 12:	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26	525 4721 9980 761. 955. 856.	ed 31/12/2006 59 .37 .38 .64 18 .82 .93	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income	Quarter ended 177 22: 399 15 4 19 12:	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04	Six months ende 525 4721 9980 761 95. 856. 368. 108.	ed 31/12/2006 59 .37 .38 .64 18 .82 .93	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax	Quarter ended 177 22: 399 15 4 19 12:	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04	DITED Six months ende 525 4721 9980 761. 95. 6368. 108. 108. 108. 108.	ed 31/12/2006 59 .37 .38 .64 18 .82 .93	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed	Quarter ended Quarter ended 177 224 391 15 44 19 12 21 10 666	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89	525 4721 9980 761. 955. 856. 368. 108. 596.	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others	Quarter ended Quarter ended 177 222 399 15 4 19 12 22 10 10 10 10 10 10 10 10 10 10 10 10 10	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 6.004 2.89	Six months ender 525 4721 9980 761. 95. 856. 368. 108. 596. 6635 -216	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others	Quarter ended Quarter ended 177 222 399 15 4 19 12 22 10 10 10 10 10 10 10 10 10 10 10 10 10	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89	525 4721 9980 761. 955. 856. 368. 108. 596.	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59
_	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed	Quarter ender Quarter ender 177 222 391 15 4 19 12 21 10 666 -21 64	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 6.46 6.953	Six months ende 528 4721 9980 761. 95. 856. 368. 108. 596. 6635 -216 6419	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ender 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
1	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- The above results as reviewed by the Audit Committee we	Quarter ended Quarter ended 177 222 399 155 44 19 12 21 10 666 -21 64 are taken on record by the Be	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 6.46 19.53 bard of Directors at it's me	Six months ende 525 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
1	Particulars Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and interest Bulk Drugs Others Total Segment Results Profit / Loss before Tax and interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fa	Quarter ender Quarter ender 177 22- 399 15 44 19 112 21 10 666 -21 64 are taken on record by the BcReview' of the financial result	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 6.04 2.89 6.46 19.53 bard of Directors at it's me is for the quarter ended 31	Six months ende 525 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
1	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen	Quarter ended Quarter ended 177 22- 399 15 4 19 12 2: 10 10 666 -21 64 ere taken on record by the Brever taken by the Brever taken by the Brever taken by	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 6.04 2.89 6.46 19.53 bard of Directors at it's me is for the quarter ended 31	Six months ende 525 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
1	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Total Capital Employed SE:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited B' in accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quant	Quarter ender Quarter ender 177 222 391 15 4 19 12 21 10 666 -21 644 ere taken on record by the Br. Review' of the financial result twith the Bombay Stock Exc. Later ended 31st Dec, 2006:	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 6.04 2.89 6.46 19.53 bard of Directors at it's me is for the quarter ended 31	Six months ende 525 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
2	SEGMENTWISE REVENUE, RESULTS AN Particulars Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen	Quarter ended Quarter ended 177 22- 399 155 44 19 12 21 10 666 -21 64 ere taken on record by the Betweise' of the financial result t with the Bombay Stock Exciter ended 31st Dec, 2006: ng - 0.	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 3.04 2.89 35.99 6.46 19.53 bard of Directors at it's me is for the quarter ended 31 shange Limited.	Six months ende 528 4721 9980 761. 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
2	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a Limited F in accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - 0, Received - 6, Disposed Off - 6 and Pendid	Quarter ended Quarter ended 177 22- 399 155 44 19 12 21 10 666 -21 64 ere taken on record by the Betweise' of the financial result t with the Bombay Stock Exciter ended 31st Dec, 2006: ng - 0.	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 3.04 2.89 35.99 6.46 19.53 bard of Directors at it's me is for the quarter ended 31 shange Limited.	Six months ende 528 4721 9980 761. 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
2	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited F in accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - 0, Received - 6, Disposed Off - 6 and Pendit The figure of Segmentwise revenue results and capital em	Quarter ended Quarter ended 177 22- 399 15 4- 19 12 2: 10 10 666 -2: 64 ere taken on record by the Beckeview' of the financial result with the Bombay Stock Excerned to the Bombay Stock Excerned of the Bombay Stock Exc	UNAL d on 31/12/2006 11.07 11.18 52.25 1.24 6.11 2.26 6.11 2.289 35.99 6.46 19.53 bard of Directors at it's me is for the quarter ended 31 shange Limited.	Six months ende 528 4721 9980 761. 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
3	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - O, Received - 6, Disposed Off - 6 and Pendi The figure of Segmentwise revenue results and capital emended 31st December, 2005 and hence not reported.	Quarter ender Quarter ender 17 22: 39: 15 4 19 12 21 10 66: -21 64 are taken on record by the Br. Review of the financial result twith the Bombay Stock Exter ended 31st Dec, 2006: ng - 0. ployed is not availale for cor	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 6.46 19.53 bard of Directors at it's me s for the quarter ended 31 thange Limited.	Six months ende 525 4721 9980 761 95. 856. 368. 108. 596. 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
3	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - O, Received - 6, Disposed Off - 6 and Pendi The figure of Segmentwise revenue results and capital emended 31st December, 2005 and hence not reported.	Quarter ended Quarter ended 177 222 399 155 44 19 12 29 10 10 666 -21 64 ere taken on record by the Betwein' of the financial result twith the Bombay Stock Exter ended 31st Dec, 2006: ng - 0. ployed is not available for corouped/restated wherever ne	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 35.99 6.46 19.53 bard of Directors at it's me is for the quarter ended 31 shange Limited. responding quarter of the pacessary.	Six months ende 528 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
3	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - O, Received - 6, Disposed Off - 6 and Pendi The figure of Segmentwise revenue results and capital emended 31st December, 2005 and hence not reported.	Quarter ended Quarter ended 177 222 399 155 44 19 12 29 10 10 666 -21 64 ere taken on record by the Betwein' of the financial result twith the Bombay Stock Exter ended 31st Dec, 2006: ng - 0. ployed is not available for corouped/restated wherever ne	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 6.46 19.53 bard of Directors at it's me s for the quarter ended 31 thange Limited.	Six months ende 528 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
3	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - O, Received - 6, Disposed Off - 6 and Pendi The figure of Segmentwise revenue results and capital emended 31st December, 2005 and hence not reported.	Quarter ended Quarter ended 177 22- 398 15 4 19 12 21 10 10 666 -21 64 erre taken on record by the Breaker of the financial result twith the Bombay Stock Exter ended 31st Dec, 2006: ang - 0. ployed is not available for control prouped/restated wherever no	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 35.99 6.46 19.53 56.46 19.53 57 or the quarter ended 31 hange Limited. responding quarter of the pacessary. For and on behalf of the B	Six months ende 528 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
3	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - O, Received - 6, Disposed Off - 6 and Pendi The figure of Segmentwise revenue results and capital emended 31st December, 2005 and hence not reported.	Quarter ended Quarter ended 177 22- 398 15 4 19 12 21 10 10 666 -21 64 erre taken on record by the Breaker of the financial result twith the Bombay Stock Exter ended 31st Dec, 2006: ang - 0. ployed is not available for control prouped/restated wherever no	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 35.99 6.46 19.53 bard of Directors at it's me is for the quarter ended 31 shange Limited. responding quarter of the pacessary.	Six months ende 528 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	AUDITED Accounting year ender 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37
3 4 6	Segment Revenue Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Revenues Segment Results Profit / Loss before tax and Interest Bulk Drugs Others Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Bulk Drugs Others Total Capital Employed ss:- Total Capital Employed ss:- The above results as reviewed by the Audit Committee we The Auditors of the Company have carried out a 'Limited Fin accordance with the Clause 41 of the Listing Agreemen The details of number of investors complaints for the quart Beginning - O, Received - 6, Disposed Off - 6 and Pendi The figure of Segmentwise revenue results and capital emended 31st December, 2005 and hence not reported.	Quarter ended Quarter ended 177 22- 399 15 4 19 12 21 10 10 666 -21 64 ever taken on record by the Beckeview of the financial result twith the Bombay Stock Excer ended 31st Dec, 2006: ng - 0. ployed is not availale for control prouped/restated wherever new prouped/restated new prou	UNAL d on 31/12/2006 11.07 11.18 52.25 4.87 1.24 6.11 2.26 9.04 2.89 35.99 6.46 19.53 56.46 19.53 57 or the quarter ended 31 hange Limited. responding quarter of the pacessary. For and on behalf of the B	Six months ende 528 4721 9980 761 95. 856. 368. 108. 596. 6635 -216 6419 eting held on 30.01.07 st December, 2006	ed 31/12/2006 59 .37 .38 .64 18 .82 .93 .94 .83	(Rs. In Lacs) AUDITED Accounting year ende 31/03/2006 7529.52 3984.06 11513.58 2274.43 28.87 2303.3 340.28 69.57 2032.59 5036.34 76.37